Fact.MR – A Market Research and Competitive Intelligence Provider: The global proliferative vitreoretinopathy market size is projected to reach US$ 660 Mn, exhibiting growth at 4.0% CAGR during the forecast period of 2018 to 2027, predicts Fact.MR.
Sales of Proliferative Vitreoretinopathy to Surge at 4.0% CAGR as Treatment with XOMA 089 Gains Traction
In its latest report, Fact.MR offers an in-depth analysis of the global proliferative vitreoretinopathy market across the leading segments, including drug type, end-user, and region. In addition, it provides elaborate information about various industry developments and strategies implemented by key players to compete in the market.
Fact.MR – A Market Research and Competitive Intelligence Provider: The global proliferative vitreoretinopathy market size is projected to reach US$ 660 Mn, exhibiting growth at 4.0% CAGR during the forecast period of 2018 to 2027, predicts Fact.MR. Increasing adoption of adjunctive treatments for the prevention of cellular proliferation is set to drive the market in the upcoming years.
Rising proliferation control and strategies associated with the enhancement of visual outcome is anticipated to propel the proliferative vitreoretinopathy market in the forthcoming years. Also, governments of various countries are providing funds to healthcare organizations for conducting research & development activities.
Further, many medical institutions are using single or weekly injections of XOMA 089 at the same dose level to inhibit proliferative vitreoretinopathy. This drug type is expected to successfully reduce detachment, degeneration, and fibrosis within the retinal compartments.
For More Valuable Information on Market Dynamics, Request a Report Sample
https://www.factmr.com/connectus/sample?flag=S&rep_id=795
As per Fact.MR, numerous companies are conducting studies with lornoxicam for the prevention of this condition. Lornoxicam has not only lowered the frequency of membrane formation, but also improved the condition of choroid and retina significantly.
Besides, inclusion of substance P in research studies have showcased its ability to suppress the development of proliferative retinopathy by preventing Epithelial-mesenchymal Transition (EMT) and apoptosis.
“Researchers are expected to focus on introducing new surgical methods to prevent Rhegmatogenous Retinal Detachment (RRD) related to proliferative vitreoretinopathy, which is anticipated to fuel the growth in the market,” says a Fact.MR analyst.
Key Takeaways:
- Based on end-user, the hospitals segment is expected to hold the lion’s share owing to the availability of safe medications for the treatment of proliferative vitreoretinopathy.
- By drug type, the XOMA-089 segment is anticipated to lead the market as it is capable of reducing the formation of the intraocular membrane and severity of retinal detachment.
- North America is likely to remain dominant in terms of market share on the back of the ongoing research activities for the development of novel treatments in the U.S.
- Asia Pacific is set to account for the second-largest market share because of the increasing adoption of preventive health care measures in China, Japan, and India.
Growth Drivers:
- Increasing research activities on the intra-retinal and peri-retinal pathology of proliferative vitreoretinopathy is set to propel the demand in the market.
- Rising usage of lornoxicam, an on-steroidal anti-inflammatory drug and SP, a neuropeptide to reduce the occurrence of this disease is likely to drive growth.
- Higher focus of scientists on finding the effective prophylaxis to eliminate the complex vitreoretinal surgical techniques for treating this disease is projected to boost the market.
Restraints:
- Various side-effects and risks associated with the treatment of proliferative vitreoretinopathy by using anti-TNF inhibitors may hinder the growth.
- Inability of researchers to draw conclusions regarding the potential treatments owing to the lower number of patients suffering from this disease is set to limit the growth.
For Critical Insights on Proliferative Vitreoretinopathy Market, Request for Methodology here
https://www.factmr.com/connectus/sample?flag=RM&rep_id=795
Competitive Landscape
Key companies operating in the proliferative vitreoretinopathy market are striving to expand their portfolios and gain a competitive edge by engaging in new product development. They are also trying to bag fast track approvals from the FDA and other government healthcare agencies to distribute their products in the market.
For instance,
- November 2021: The United States Department of Defense (DoD) provided funds worth US$1.27 million to Weill Cornell Medicine for conducting research on proliferative vitreoretinopathy. The research will help the company to develop the treatment of this rare eye condition. Tests will be conducted on animal models and A2-blocking antibodies will be injected in their injured eye to determine whether these can prevent the condition.
- July 2021: Aldeyra Therapeutics, Inc., a commercial stage oncology company based in the U.S., received the orphan drug designation from the FDA for its ADX-2191 (methotrexate for intravitreal injection). It can now be used to treat Primary Vitreoretinal Lymphoma (PVRL). This approval would complement the company’s ongoing clinical development of ADX-2191 for the treatment of proliferative vitreoretinopathy.
- June 2018: The U.S.-based Wills Eye Hospital announced the results of its clinical trial to explore the effect of oral isotretinoin for the prevention of proliferative vitreoretinopathy. The participants were given 20mg isotretinoin regularly for twelve weeks. As per the hospital, the drug can reduce the risk of recurrent retinal detachment in eyes associated with proliferative vitreoretinopathy.
Key Players in the Proliferative Vitreoretinopathy Market Include:
- Genentech, Inc.
- Novartis AG
- Allergan plc
- Regeneron Pharmaceuticals, Inc.
- RXi Pharmaceuticals Corp.
- Promedior, Inc.
- Others
More Valuable Insights on Proliferative Vitreoretinopathy Market
Fact.MR provides an unbiased analysis of the proliferative vitreoretinopathy market, presenting historical demand data (2012-2017) and forecast statistics for the period from 2018-2027. The study divulges compelling insights on the global proliferative vitreoretinopathy market with a detailed segmentation on the basis of:
Drug Type
- PRM-167
- XOMA-089
- Others
End-user
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Key Questions Covered in Proliferative Vitreoretinopathy Market Report
- The report offers insight into the proliferative vitreoretinopathy market demand outlook for 2018-2027.
- The market study also highlights projected sales growth for proliferative vitreoretinopathy market between 2018 and 2027.
- Proliferative vitreoretinopathy market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry.
- Proliferative vitreoretinopathy market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain -
Artificial Retina Market Insights - An artificial retina is a biological device that is surgically implanted into the eyes to improve vision loss. This implant converts an image into an electrical signal that is sent to a nerve cell, allowing it to recognize the image in the presence of light, allowing for improved vision in the future. The growing elderly population, as well as enormous innovation and substantial investment in the field of retina, are driving the market. The expansion of this market is fuelled by government initiatives in the healthcare sector, such as providing more funding to the healthcare department.
Mobile Retina Services Market Forecast - The market for mobile retina services is being driven by a rising number of diabetic patients with retinopathy, patients having laser treatments, and routine diagnostics due to increased awareness. The availability of emergency assistance at the site of the incident will enhance demand for mobile retina services and alter public view of the vision business. Another motivator could be that a geriatric population with partial visual loss prefers to make appointments at home or at a preferred location rather than going to the clinic.
Retinal Biosimilars Market Scope - Although the retinal biosimilars industry is still in its early stages, it is likely to grow rapidly in the future years. Local and regional businesses compete fiercely in the market for retinal biosimilars. In the worldwide retinal biosimilars market, the retinoblastoma and macular degeneration indication segments are likely to lead. In the retinal biosimilars market, the hospital pharmacies segment by distribution channel is predicted to contribute a large market revenue share.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to chemical and materials, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our chemical and materials research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR